Deciphera Pharmaceuticals Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

Deciphera Pharmaceuticals wird ein jährliches Gewinn- und Umsatzwachstum von 50.6% bzw. 23.6% prognostiziert. Der Gewinn pro Aktie wird voraussichtlich wachsen um 52.1% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich -50.1% betragen.

Wichtige Informationen

50.6%

Wachstumsrate der Gewinne

52.1%

EPS-Wachstumsrate

Biotechs Gewinnwachstum	28.4%
Wachstumsrate der Einnahmen	23.6%
Zukünftige Eigenkapitalrendite	-50.1%
Analystenabdeckung	Good
Zuletzt aktualisiert	11 Jun 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Deciphera Pharmaceuticals, Inc.'s (NASDAQ:DCPH) 61% Share Price Surge Not Quite Adding Up

Apr 30

Diving Into Deciphera Pharmaceuticals

Apr 26

We Think Deciphera Pharmaceuticals (NASDAQ:DCPH) Can Afford To Drive Business Growth

Mar 13

We Think Deciphera Pharmaceuticals (NASDAQ:DCPH) Can Afford To Drive Business Growth

Dec 02

Are Investors Undervaluing Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) By 41%?

Sep 25

Deciphera Pharmaceuticals (NASDAQ:DCPH) Is In A Good Position To Deliver On Growth Plans

Jul 26

Calculating The Intrinsic Value Of Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH)

Jun 22

Lacklustre Performance Is Driving Deciphera Pharmaceuticals, Inc.'s (NASDAQ:DCPH) Low P/S

May 08

We Think Deciphera Pharmaceuticals (NASDAQ:DCPH) Can Afford To Drive Business Growth

Apr 10

We Think Deciphera Pharmaceuticals (NASDAQ:DCPH) Can Afford To Drive Business Growth

Dec 29

Deciphera initiated at buy at Cowen on Qinlock growth, pipeline; sees 68% upside

Aug 29

Deciphera Pharmaceuticals Q2 2022 Earnings Preview

Aug 03

We Think Deciphera Pharmaceuticals (NASDAQ:DCPH) Needs To Drive Business Growth Carefully

Jul 29

Deciphera Pharmaceuticals: Not Too Happy With The Risk-Reward Right Now

Feb 11

Deciphera Pharmaceuticals: The 75% Haircut Doesn't Seem Justified

Nov 22

Deciphera Pharmaceuticals (NASDAQ:DCPH) Is In A Good Position To Deliver On Growth Plans

Aug 26

Deciphera Pharmaceuticals posts data from cancer studies at ASCO21

Jun 04

Companies Like Deciphera Pharmaceuticals (NASDAQ:DCPH) Are In A Position To Invest In Growth

May 10

Gewinn- und Umsatzwachstumsprognosen

NasdaqGS:DCPH - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	377	-72	-49	-113	7
12/31/2025	265	-157	-145	-152	8
12/31/2024	204	-186	-176	-154	5
3/31/2024	175	-190	-152	-152	N/A
12/31/2023	163	-195	-147	-147	N/A
9/30/2023	151	-194	-154	-153	N/A
6/30/2023	144	-187	-145	-144	N/A
3/31/2023	138	-182	-152	-151	N/A
12/31/2022	134	-179	-154	-153	N/A
9/30/2022	122	-221	-185	-185	N/A
6/30/2022	109	-258	-223	-218	N/A
3/31/2022	100	-286	-230	-224	N/A
12/31/2021	96	-300	-247	-241	N/A
9/30/2021	91	-274	-230	-223	N/A
6/30/2021	84	-258	-221	-218	N/A
3/31/2021	67	-255	-232	-227	N/A
12/31/2020	42	-266	-245	-240	N/A
9/30/2020	23	-271	-253	-246	N/A
6/30/2020	7	-263	-229	-220	N/A
3/31/2020	25	-218	-202	-197	N/A
12/31/2019	25	-192	-154	-149	N/A
9/30/2019	25	-157	-124	-120	N/A
6/30/2019	25	-126	-123	-122	N/A
3/31/2019	N/A	-126	-104	-103	N/A
12/31/2018	N/A	-100	-88	-87	N/A
9/30/2018	N/A	-87	-74	-73	N/A
6/30/2018	N/A	-75	-58	-57	N/A
3/31/2018	N/A	-64	-47	-46	N/A
12/31/2017	N/A	-50	N/A	-37	N/A
9/30/2017	N/A	-39	N/A	-31	N/A
6/30/2017	N/A	-33	N/A	-28	N/A
3/31/2017	N/A	-28	N/A	-25	N/A
12/31/2016	N/A	-26	N/A	-23	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: DCPH wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Ertrag vs. Markt: DCPH wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Hohe Wachstumserträge: DCPH wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Einnahmen vs. Markt: DCPHDie Einnahmen des Unternehmens (23.6% pro Jahr) werden voraussichtlich schneller wachsen als der Markt US (9% pro Jahr).

Hohe Wachstumseinnahmen: DCPHDie Einnahmen des Unternehmens (23.6% pro Jahr) werden voraussichtlich schneller wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: DCPH wird voraussichtlich in 3 Jahren unrentabel sein.

Deciphera Pharmaceuticals Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Price target increased by 7.1% to US$25.38

Consensus estimates of losses per share improve by 12%

Deciphera Pharmaceuticals, Inc. Provides Earnings Guidance for the Fourth Quarter and Full Year Ended December 31, 2023

Price target increased by 11% to US$24.44

Price target increased to US$21.10

Deciphera Pharmaceuticals, Inc. Provides Preliminary Unaudited Revenue Guidance for the Fourth Quarter and Full Year 2022

Recent updates

Deciphera Pharmaceuticals, Inc. Files Form 15

Deciphera Pharmaceuticals, Inc.(NasdaqGS:DCPH) dropped from NASDAQ Composite Index

Deciphera Pharmaceuticals Announces Oral Presentation of Results from Motion Pivotal Phase 3 Study of Vimseltinib in Patients with Tenosynovial Giant Cell Tumor (Tgct) At the 2024 Asco Annual Meeting and Online Publication in the Lancet

First quarter 2024 earnings released: US$0.52 loss per share (vs US$0.60 loss in 1Q 2023)

Ono Pharmaceutical Co., Ltd. (TSE:4528) entered into a definitive merger agreement to acquire Deciphera Pharmaceuticals, Inc. (NasdaqGS:DCPH) for $2.2 billion.

Deciphera Pharmaceuticals, Inc.'s (NASDAQ:DCPH) 61% Share Price Surge Not Quite Adding Up

Ono Pharmaceutical Co., Ltd. (TSE:4528) entered into a definitive merger agreement to acquire Deciphera Pharmaceuticals, Inc. (NasdaqGS:DCPH) for $2.2 billion.

Price target increased by 7.1% to US$25.38

Deciphera Pharmaceuticals, Inc., Annual General Meeting, Jun 20, 2024

Diving Into Deciphera Pharmaceuticals

We Think Deciphera Pharmaceuticals (NASDAQ:DCPH) Can Afford To Drive Business Growth

Full year 2023 earnings: EPS exceeds analyst expectations

Consensus estimates of losses per share improve by 12%

Deciphera Pharmaceuticals, Inc. to Report Q4, 2023 Results on Feb 06, 2024

Deciphera Pharmaceuticals, Inc. Provides Earnings Guidance for the Fourth Quarter and Full Year Ended December 31, 2023

Deciphera Pharmaceuticals Announces Nature Medicine Publication of Results from Exploratory ctDNA Analysis from INTRIGUE Phase 3 Study Demonstrating Substantial Clinical Benefit of QINLOCK® in 2L GIST Patients with Mutations in KIT Exon 11 and 17/18

President recently sold US$471k worth of stock

Senior VP & Chief Commercial Officer recently sold US$224k worth of stock

We Think Deciphera Pharmaceuticals (NASDAQ:DCPH) Can Afford To Drive Business Growth

President recently sold US$259k worth of stock

Price target increased by 11% to US$24.44

Deciphera Pharmaceuticals, Inc. Announces Positive Top-Line Results from Motion Pivotal Phase 3 Study of Vimseltinib in Patients with Tenosynovial Giant Cell Tumor

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Are Investors Undervaluing Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) By 41%?

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Deciphera Pharmaceuticals, Inc. Announces Board Changes, Effective from September 5, 2023

Deciphera Pharmaceuticals, Inc. to Report Q2, 2023 Results on Aug 09, 2023

Deciphera Pharmaceuticals (NASDAQ:DCPH) Is In A Good Position To Deliver On Growth Plans

Calculating The Intrinsic Value Of Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH)

Deciphera Pharmaceuticals, Inc. to Present Data from INTRIGUE Phase 3 Study of QINLOCK (ripretinib) and Trial-In-Progress Poster for Insights Pivotal Phase 3 Study of QINlock (Rpretinib) at the 2023 American Society of Clinical Oncology Annual Meeting

Independent Director recently bought US$152k worth of stock

Lacklustre Performance Is Driving Deciphera Pharmaceuticals, Inc.'s (NASDAQ:DCPH) Low P/S

First quarter 2023 earnings: EPS and revenues miss analyst expectations

We Think Deciphera Pharmaceuticals (NASDAQ:DCPH) Can Afford To Drive Business Growth

President notifies of intention to sell stock

Full year 2022 earnings: EPS exceeds analyst expectations

Deciphera Pharmaceuticals, Inc. to Report Q4, 2022 Results on Feb 07, 2023

Deciphera Pharmaceuticals, Inc. Presents Results from ctDNA Analysis of INTRIGUE Phase 3 Clinical Study at the American Society of Clinical Oncology Plenary Series Session

Executive VP recently sold US$51k worth of stock

Now 20% undervalued

Price target increased to US$21.10

Deciphera Pharmaceuticals, Inc. Provides Preliminary Unaudited Revenue Guidance for the Fourth Quarter and Full Year 2022

Price target increased to US$20.25

Deciphera Pharmaceuticals, Inc. Pharmaceuticals Announces Results from ctDNA Analysis from INTRIGUE Phase 3 Clinical Study Demonstrating Substantial Clinical Benefit of QINLOCK in Second-Line GIST Patients with Mutations in KIT Exon 11 and 17/18 Only

We Think Deciphera Pharmaceuticals (NASDAQ:DCPH) Can Afford To Drive Business Growth

Insufficient new directors

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Deciphera Pharmaceuticals, Inc. to Report Q3, 2022 Results on Nov 03, 2022

Deciphera Pharmaceuticals, Inc. Presents Updated Phase 1/2 Data for Vimseltinib in TGCT at the European Society for Medical Oncology (ESMO) Congress 2022

Deciphera Pharmaceuticals, Inc. Presents Initial Phase 1 Single Agent Dose Escalation Data for First-in-Class ULK Inhibitor of Autophagy, DCC-3116, at the European Society for Medical Oncology (ESMO) Congress 2022

Deciphera initiated at buy at Cowen on Qinlock growth, pipeline; sees 68% upside

Deciphera Pharmaceuticals, Inc. Announces Publication of Intrigue Phase 3 Clinical Study Results in Journal of Clinical Oncology

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

Deciphera Pharmaceuticals Q2 2022 Earnings Preview

Deciphera Pharmaceuticals, Inc. to Report Q2, 2022 Results on Aug 04, 2022

We Think Deciphera Pharmaceuticals (NASDAQ:DCPH) Needs To Drive Business Growth Carefully

Deciphera Pharmaceuticals, Inc. Appoints Kelley Dealhoy as Senior Vice President and Chief Business Officer

First quarter 2022 earnings: EPS and revenues exceed analyst expectations

Deciphera Pharmaceuticals, Inc. to Report Q1, 2022 Results on May 04, 2022

Insufficient new directors

Deciphera Pharmaceuticals, Inc Presents Preclinical Data from DCC-3116 Program At the AACR Annual Meeting

Insufficient new directors

Deciphera Pharmaceuticals: Not Too Happy With The Risk-Reward Right Now

Deciphera Pharmaceuticals, Inc. to Report Q4, 2021 Results on Feb 08, 2022

Deciphera Pharmaceuticals, Inc. Presents Results from the INTRIGUE Phase 3 Clinical Study at the American Society of Clinical Oncology Plenary Series Session

Deciphera Announces Approval of QINLOCK® in the United Kingdom for the Treatment of Fourth-Line Gastrointestinal Stromal Tumor

Deciphera Pharmaceuticals, Inc. Receives European Commission Approval of QINLOCK® for Treatment of Fourth-Line Gastrointestinal Stromal Tumor

Deciphera Pharmaceuticals: The 75% Haircut Doesn't Seem Justified

Price target decreased to US$59.27